A patient has an INR of 1.6 (reference 0.9‑1.2), prothrombin time of 19.9 seconds (reference 12.2‑14.9), and activated partial thromboplastin time of 70 seconds (markedly prolonged) with easy bruising. What is the likely cause and appropriate management?

Coagulopathy Workup: Combined PT/aPTT Prolongation with Easy Bruising

Most Likely Diagnosis

This patient most likely has lupus anticoagulant (LA), which is the most common cause of isolated prolonged aPTT (markedly elevated at 70 seconds) combined with mild PT prolongation (INR 1.6) in an outpatient presenting with easy bruising. 1, 2, 3

Diagnostic Approach

Pattern Recognition

The coagulation pattern shows:

• Markedly prolonged aPTT (70 seconds) - this is the dominant abnormality 3
• Mildly prolonged PT/INR (19.9 sec, INR 1.6) - lupus anticoagulants typically cause only slight PT prolongation 1
• Easy bruising as the clinical presentation 2

This specific pattern (dramatically prolonged aPTT with mild PT elevation) strongly suggests lupus anticoagulant rather than factor deficiency or anticoagulant medication 1, 4, 3.

Immediate Next Steps

Order mixing studies immediately to differentiate between:

• Factor deficiency (mixing study corrects) 5, 6
• Inhibitor present (mixing study does not correct) 7, 8, 6

If the mixing study shows non-correction, proceed with:

• Dilute Russell's viper venom time (dRVVT) 8
• Hexagonal phase phospholipid neutralization 3
• Anticardiolipin antibodies 4
• Anti-beta-2 glycoprotein I antibodies 4

Critical Laboratory Considerations

The PT reagent type matters significantly - recombinant thromboplastin reagents (like Innovin®) are more susceptible to LA interference than tissue-derived reagents (like Thromborel® S) 4. If LA is suspected and PT is prolonged, consider retesting with a tissue-derived reagent to confirm true PT prolongation versus LA artifact 4.

Lupus anticoagulants prolong aPTT markedly but usually cause only slight PT prolongation according to the reagents used 1.

Differential Diagnosis by Likelihood

Most Common (64% of cases)

Acquired conditions 2:

1. Lupus anticoagulant - most common cause of isolated prolonged aPTT (5% of cases with isolated aPTT prolongation) 2, 3
2. Anticoagulant therapy - particularly heparin contamination or unfractionated heparin 3, 8
3. Liver disease - most common cause when both PT and aPTT are prolonged (14% of combined prolongation cases) 1, 2
4. Vitamin K deficiency - most common cause of isolated PT prolongation (10% of cases) 2

Less Common (22% of cases)

Congenital factor deficiencies 2:

• Factor VIII, IX, XI deficiencies (hemophilia spectrum) 3, 7
• Factor XII deficiency (does not cause bleeding) 7

Rare (9% of cases)

Acquired factor inhibitors 2, 8:

• Acquired hemophilia A (anti-factor VIII antibodies) 8
• Other specific factor inhibitors 7

Artifact (5% of cases)

Laboratory/preanalytical issues 2:

• Underfilled collection tubes (excess citrate) 1
• Heparin contamination from IV lines 3, 8
• Sample handling errors 5

Management Algorithm

If Lupus Anticoagulant Confirmed:

• LA does NOT predict bleeding risk - paradoxically indicates thrombotic risk 1, 4
• Easy bruising may be coincidental or from another cause 3
• Do not use INR for warfarin monitoring in LA-positive patients - consider chromogenic factor X assay or prothrombin/proconvertin tests instead 1
• Evaluate for antiphospholipid syndrome criteria 4

If Factor Deficiency Identified:

• Quantify specific factor levels 7, 8
• Determine if congenital (lifelong history) or acquired (recent onset) 2
• Consider factor replacement if levels critically low and bleeding present 8

If Anticoagulant Medication:

• Check medication history thoroughly including over-the-counter products 3
• Measure anti-Xa levels if heparin suspected 1, 3
• Consider direct oral anticoagulant (DOAC) levels if recent use 1

Common Pitfalls to Avoid

Do not assume prolonged coagulation tests always indicate bleeding risk - lupus anticoagulant causes test prolongation but increases thrombosis risk, not bleeding 1, 4, 3.

Do not rely on INR alone - subtle PT changes may not be detected when reported as INR rather than PT in seconds 1.

Do not overlook preanalytical variables - underfilled tubes with excess citrate spuriously prolong PT 1, 5.

Do not use recombinant PT reagents for LA patients - they show greater interference than tissue-derived reagents 4.

Do not skip mixing studies - they are essential for differentiating factor deficiency from inhibitors and guide all subsequent testing 5, 6.